Literature DB >> 78137

Doxorubicin for liver cancer.

J Vilaseca, J Guardia, R Bacardi, J Monné.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 78137     DOI： 10.1016/s0140-6736(78)92448-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.

Authors:  Ziqiang Ding; Dujin Wang; Wei Shi; Xiaomei Yang; Siliang Duan; Fengzhen Mo; Xiaoqiong Hou; Aiqun Liu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2020-10-29

2.  Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells.

Authors:  Bo Li; Do Sung Kim; Raj Kumar Yadav; Hyung Ryong Kim; Han Jung Chae
Journal:  Int J Mol Med       Date:  2015-04-28       Impact factor: 4.101

3.  MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.

Authors:  Yin-Ping Fan; Jia-Zhi Liao; Ya-Qi Lu; De-An Tian; Feng Ye; Peng-Xuan Zhao; Guang-Ya Xiang; Wang-Xian Tang; Xing-Xing He
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-06

4.  68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity.

Authors:  Jothilingam Sivapackiam; Shivesh Kabra; Sylvia Speidel; Monica Sharma; Richard Laforest; Amber Salter; Michael P Rettig; Vijay Sharma
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

5.  Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells.

Authors:  Qingqing Xiong; Mangmang Cui; Ge Yu; Jian Wang; Tianqiang Song
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.